iRhythm Holdings, Inc. filings document the public-company reporting of a digital health care business centered on ambulatory cardiac monitoring. Recent Form 8-K disclosures report operating results, financial condition, guidance-related exhibits, Regulation FD materials, material agreements, executive compensation policy changes, board appointments, and changes in the independent registered public accounting firm.
Proxy materials cover director elections, board and committee structure, executive compensation, equity awards, and stockholder voting matters. The filing record also documents the completed holding-company reorganization under which iRhythm Holdings became successor registrant to iRhythm Technologies, including common-stock continuity and predecessor registration-termination records.
Form 144 summary: Form 144 notifies a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) on NASDAQ, approximate sale date 08/05/2025. Aggregate market value is reported as $4,816,190.87 and shares outstanding are reported as 32,127,763.
Acquisition history and disclosures: The form lists three acquisitions that total 30,000 shares—restricted stock 11/01/2023: 7,449; open-market purchase 06/06/2023: 9,755 (paid cash); restricted stock 11/01/2022: 12,796. The form states "Nothing to Report" for securities sold during the past three months. Several identification fields (filer CIK, issuer name, date of notice, signature) are blank in the provided content.